Knight Therapeutics Statistics
Knight Therapeutics (04K) Stock Statistics & Valuation Metrics
Total Valuation
Knight Therapeutics has a market cap or net worth of EUR 707.79M. The enterprise value is EUR 936.94M.
- Market Cap
- EUR 707.79M
- Enterprise Value
- EUR 936.94M
Share Statistics
Knight Therapeutics has 98,231,610 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 98,231,610
- Owned by Insiders
- 23.43%
- Owned by Institutions
- 4.85%
Financial Efficiency
Knight Therapeutics’s return on equity (ROE) is -0.01 and return on invested capital (ROIC) is -0.20%.
- Return on Equity (ROE)
- -0.01
- Return on Assets (ROA)
- -0.01
- Return on Invested Capital (ROIC)
- -0.20%
- Return on Capital Employed (ROCE)
- -0.00
- Revenue Per Employee
- 542.27K
- Profits Per Employee
- -6,474.699
- Employee Count
- 830
- Asset Turnover
- 0.43
- Inventory Turnover
- 2.20
Valuation Ratios
The current PE Ratio of Knight Therapeutics is 74.79. Knight Therapeutics’s PEG ratio is 0.26.
- PE Ratio
- 74.79
- PS Ratio
- 2.02
- PB Ratio
- 1.43
- Price to FCF
- 9.59
- Price to Operating Cash Flow
- 8.87
- PEG Ratio
- 0.26
Income Statement
In the last 12 months, Knight Therapeutics had revenue of 450.09M and earned -5.37M in profits. Earnings per share was -0.05.
- Revenue
- 450.09M
- Gross Profit
- 150.74M
- Operating Income
- -2.20M
- Pretax Income
- -6.70M
- Net Income
- -5.37M
- EBITDA
- 54.37M
- Earnings Per Share (EPS)
- -0.05
Cash Flow
In the last 12 months, operating cash flow was 128.43M and capital expenditures -9.56M, giving a free cash flow of 118.88M billion.
- Operating Cash Flow
- 128.43M
- Free Cash Flow
- 118.88M
- Free Cash Flow per Share
- 1.21
Dividends & Yields
Knight Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 10.41%
- Earnings Yield
- 1.40%
Stock Price Statistics
- Beta
- 0.01
- 52-Week Price Change
- 106.46%
- 50-Day Moving Average
- 6.62
- 200-Day Moving Average
- 5.43
- Relative Strength Index (RSI)
- 68.47
- Average Volume (3m)
- ―
Important Dates
Knight Therapeutics upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Knight Therapeutics as a current ratio of 2.39, with Debt / Equity ratio of 10.15%
- Current Ratio
- 2.39
- Quick Ratio
- 1.57
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- 0.03
- Interest Coverage Ratio
- -0.21
Taxes
In the past 12 months, Knight Therapeutics has paid -1.33M in taxes.
- Income Tax
- -1.33M
- Effective Tax Rate
- 0.20
Enterprise Valuation
Knight Therapeutics EV to EBITDA ratio is 12.36, with an EV/FCF ratio of 8.88.
- EV to Sales
- 1.87
- EV to EBITDA
- 12.36
- EV to Free Cash Flow
- 8.88
- EV to Operating Cash Flow
- 8.22
Balance Sheet
Knight Therapeutics has EUR 147.83M in cash and marketable securities with EUR 33.52M in debt, giving a net cash position of EUR 114.31M billion.
- Cash & Marketable Securities
- EUR 147.83M
- Total Debt
- EUR 33.52M
- Net Cash
- EUR 114.31M
- Net Cash Per Share
- EUR 1.16
- Tangible Book Value Per Share
- EUR 3.59
Margins
Gross margin is 40.80%, with operating margin of 5.55%, and net profit margin of 2.84%.
- Gross Margin
- 40.80%
- Operating Margin
- 5.55%
- Pretax Margin
- 3.27%
- Net Profit Margin
- 2.84%
- EBITDA Margin
- 15.15%
- EBIT Margin
- 4.06%
Analyst Forecast
The average price target for Knight Therapeutics is EUR 8.15, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 8.15
- Price Target Upside
- 10.95% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- 30.84%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 9
- AI Score
- ―
